A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254

Richard R. Furman; Michael L. Grossbard; Jeffrey L. Johnson; Andrew L. Pecora; Peter A. Cassileth; Sin Ho Jung; Bruce A. Peterson; Lee M. Nadler; Arnold Freedman; Ruthee Lu Bayer; Nancy L. Bartlett; David D. Hurd; Bruce D. Cheson

doi:10.3109/10428194.2010.543714

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254

Richard R. Furman
, Michael L. Grossbard
, Jeffrey L. Johnson
, Andrew L. Pecora
, Peter A. Cassileth
, Sin Ho Jung
, Bruce A. Peterson
, Lee M. Nadler
, Arnold Freedman
, Ruthee Lu Bayer
, Nancy L. Bartlett
, David D. Hurd
, Bruce D. Cheson

School of Medicine

Hackensack Meridian School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which randomized 157 patients with B-cell lymphoma in complete remission following autologous transplant to treatment with anti-B4-bR or observation. With a median follow-up time for patients of 5.8 years, the median event-free survival for protocol treatment and observation are 2.1 and 2.9 years, respectively (p = 0.275). The median overall survival for treatment and observation are 6.1 years and not reached, respectively (p = 0.063). Therefore, no differences were found in event-free survival and overall survival between protocol treatment and observation, although there was a trend toward improved survival with observation. These data fail to support a role for anti-B4-bR as consolidative therapy after bone marrow transplant in patients with B-cell lymphoma.

Original language	English
Pages (from-to)	587-596
Number of pages	10
Journal	Leukemia and Lymphoma
Volume	52
Issue number	4
DOIs	https://doi.org/10.3109/10428194.2010.543714
State	Published - Apr 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Keywords

Lymphoma
adjuvant therapy
anti-B4-blocked ricin
autologous transplant

Access to Document

10.3109/10428194.2010.543714

Cite this

Furman, R. R., Grossbard, M. L., Johnson, J. L., Pecora, A. L., Cassileth, P. A., Jung, S. H., Peterson, B. A., Nadler, L. M., Freedman, A., Bayer, R. L., Bartlett, N. L., Hurd, D. D., & Cheson, B. D. (2011). A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leukemia and Lymphoma, 52(4), 587-596. https://doi.org/10.3109/10428194.2010.543714

@article{9c812f94717e4a46b4f84a769525fa77,

title = "A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254",

abstract = "Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which randomized 157 patients with B-cell lymphoma in complete remission following autologous transplant to treatment with anti-B4-bR or observation. With a median follow-up time for patients of 5.8 years, the median event-free survival for protocol treatment and observation are 2.1 and 2.9 years, respectively (p = 0.275). The median overall survival for treatment and observation are 6.1 years and not reached, respectively (p = 0.063). Therefore, no differences were found in event-free survival and overall survival between protocol treatment and observation, although there was a trend toward improved survival with observation. These data fail to support a role for anti-B4-bR as consolidative therapy after bone marrow transplant in patients with B-cell lymphoma.",

keywords = "Lymphoma, adjuvant therapy, anti-B4-blocked ricin, autologous transplant",

author = "Furman, \{Richard R.\} and Grossbard, \{Michael L.\} and Johnson, \{Jeffrey L.\} and Pecora, \{Andrew L.\} and Cassileth, \{Peter A.\} and Jung, \{Sin Ho\} and Peterson, \{Bruce A.\} and Nadler, \{Lee M.\} and Arnold Freedman and Bayer, \{Ruthee Lu\} and Bartlett, \{Nancy L.\} and Hurd, \{David D.\} and Cheson, \{Bruce D.\}",

year = "2011",

month = apr,

doi = "10.3109/10428194.2010.543714",

language = "English",

volume = "52",

pages = "587--596",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor and Francis Ltd.",

number = "4",

}

Furman, RR, Grossbard, ML, Johnson, JL, Pecora, AL, Cassileth, PA, Jung, SH, Peterson, BA, Nadler, LM, Freedman, A, Bayer, RL, Bartlett, NL, Hurd, DD & Cheson, BD 2011, 'A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254', Leukemia and Lymphoma, vol. 52, no. 4, pp. 587-596. https://doi.org/10.3109/10428194.2010.543714

TY - JOUR

T1 - A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant

T2 - CALGB 9254

AU - Furman, Richard R.

AU - Grossbard, Michael L.

AU - Johnson, Jeffrey L.

AU - Pecora, Andrew L.

AU - Cassileth, Peter A.

AU - Jung, Sin Ho

AU - Peterson, Bruce A.

AU - Nadler, Lee M.

AU - Freedman, Arnold

AU - Bayer, Ruthee Lu

AU - Bartlett, Nancy L.

AU - Hurd, David D.

AU - Cheson, Bruce D.

PY - 2011/4

Y1 - 2011/4

N2 - Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which randomized 157 patients with B-cell lymphoma in complete remission following autologous transplant to treatment with anti-B4-bR or observation. With a median follow-up time for patients of 5.8 years, the median event-free survival for protocol treatment and observation are 2.1 and 2.9 years, respectively (p = 0.275). The median overall survival for treatment and observation are 6.1 years and not reached, respectively (p = 0.063). Therefore, no differences were found in event-free survival and overall survival between protocol treatment and observation, although there was a trend toward improved survival with observation. These data fail to support a role for anti-B4-bR as consolidative therapy after bone marrow transplant in patients with B-cell lymphoma.

AB - Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which randomized 157 patients with B-cell lymphoma in complete remission following autologous transplant to treatment with anti-B4-bR or observation. With a median follow-up time for patients of 5.8 years, the median event-free survival for protocol treatment and observation are 2.1 and 2.9 years, respectively (p = 0.275). The median overall survival for treatment and observation are 6.1 years and not reached, respectively (p = 0.063). Therefore, no differences were found in event-free survival and overall survival between protocol treatment and observation, although there was a trend toward improved survival with observation. These data fail to support a role for anti-B4-bR as consolidative therapy after bone marrow transplant in patients with B-cell lymphoma.

KW - Lymphoma

KW - adjuvant therapy

KW - anti-B4-blocked ricin

KW - autologous transplant

UR - https://www.scopus.com/pages/publications/79953220503

U2 - 10.3109/10428194.2010.543714

DO - 10.3109/10428194.2010.543714

M3 - Article

C2 - 21275630

SN - 1042-8194

VL - 52

SP - 587

EP - 596

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 4

ER -

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254

Abstract

UN SDGs

ASJC Scopus subject areas

Keywords

Access to Document

Other files and links

Fingerprint

Cite this